Though “skepticism” flies on the Street surrounding Tesla’s Model 3 production challenges, Guggenheim’s Rob Cihra bats for the bulls on Tesla’s odds to hit profitability.
On back of a solid swing for VRX’s rebounding momentum, BTIG’s Tim Chiang sheds light on Q1 earnings and a forthcoming name change.
Here’s why even bullish analyst Ram Selvaraju of H.C. Wainwright is tweaking his estimates on SGYP in anticipation of the quarterly show.
Oppenheimer’s Leah R. Cann and Canaccord’s John Newman are out with bullish research notes following this biotech giant’s first quarter print.
Cowen’s Chris Shibutani remains confident on AKAO as he angles for plazomicin’s timely approval in cUTI by the end of June.